Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05222594 · ClinicalTrials.gov registry record · NA

Computational Neuroscience of Language Processing in the Human Brain

A NA study of Epilepsy and Language, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05222594: Recruiting NA study of Epilepsy and Language, sponsored by Massachusetts General Hospital.

NCT05222594 is a NA study of Epilepsy and Language that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05222594, a NA study of Epilepsy and Language, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Language is a signature human cognitive skill, but the precise computations that support language understanding remain unknown. This study aims to combine high-quality human neural data obtained through intracranial recordings with advances in computational modeling of human cognition to shed light on the construction and understanding of speech.

Primary Outcome

By using sEEG intracranial recordings of the brain, EEG power in frequency bands will reflect cortical maps of responses to different linguistic manipulations, informing the functional organization of the human language system. Power is measured in arbitrary units; higher power reflects greater activity at the investigated frequency.

Conditions Studied

Interventions

  • OTHER Behavioral tasks during intracranial monitoring

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-04-02
Est. Completion 2026-03-31
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05222594 shows while recruiting

NCT05222594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Behavioral tasks during intracranial monitoring is the first listed.

NCT05222594 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05222594 about?

NCT05222594 is a clinical study titled "Computational Neuroscience of Language Processing in the Human Brain". Language is a signature human cognitive skill, but the precise computations that support language understanding remain unknown. This study aims to combine high-quality human neural data obtained through intracranial recordings with advances in computational modeling of human cognition to shed light ...

What is the current status of trial NCT05222594?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2021-04-02. Estimated completion is 2026-03-31.

What conditions does trial NCT05222594 study?

This clinical trial studies the following conditions: Epilepsy, Language.

What interventions are being tested in trial NCT05222594?

The interventions under investigation include: Behavioral tasks during intracranial monitoring (OTHER).

Who is sponsoring clinical trial NCT05222594?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05222594 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05222594's enrollment target sits among peer trials

40 92nd of 160 higher than 61 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05222594, the US trial registry maintained by the National Library of Medicine. NCT05222594 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.